Clinical Characterization and Treatment of Hospitalized COVID-19 Patients in Cuban Intensive Care Units
Keywords:
coronavirus, COVID-19, SARS-CoV-2, clinical protocols, Cuba.Abstract
Introduction: COVID-19 pandemic was declared an international public health emergency. The knowledge of the symptoms, comorbidities, and the risk associated with the treatment received could contribute to better classification and care of patients.
Objective: To clinically characterize COVID-19 patients admitted to the Cuban intensive care units
Methods: A retrospective observational study of all patients treated in the Cuban intensive care units from March 11 to July 30, 2020. Demographic, clinical and outcome data were collected. The prevalence of fatal and recovery cases was compared by covariables using the standard chi-square test. A logistic regression was performed to evaluate the predictor variables for in-hospital mortality.
Results: A total of 175 patients were treated, including 106 acutely ill and 69 critically ill. Patients were predominantly male (52.0%), over 60 years old (67.2%) and had hypertension (57.0%). Age (over 80 years old, OR= 9.62, 95% CI: 3.16-29.2), health status at admission (OR= 8.32, 95% CI: 2.30-30.10), and hemodynamic instability (OR=6.9, 95% CI: 2.96-16.37) were associated with an increased risk of death. Patients treated with Kaletra, chloroquine, Itolizumab, or Jusvinza increased survival. Mortality risk in critically ill patients decreased from 80% to 25% with the use of Jusvinza.
Conclusions: The clinical characterization performed demonstrates the effectiveness of the clinical protocols used in the country’s intensive care units.
Downloads
References
- World Health Organization [Internet]. Coronavirus disease (COVID-19). Situation Report-105. [Internet].Ginebra: WHO; 2020 [acceso 6/04/2020]. Disponible en:http://www.who.int/docs/default-source/coronaviruse/situation-reports/20200719-covid-19-sitrep-181.pdf?sfvrsn=82352496_2
- Cheng C, Barceló J, Hartnett AS, Kubinec R, Messerschmidt L. COVID-19 Government Response Event Dataset (CoronaNet v.1.0). Nat Hum Behav. [Internet]. 2020 [acceso 7/07/20]; 4(7):756-68. Disponible en: http://doi.org/10.1038/s41562-020-0909-7
- Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet]. 2020 [acceso 7/07/2020]; 395: 1054–62. Disponible en: http://doi.org/10.1016/S0140-6736(20)30566-3
- Pérez-Guzman PN, Daunt A, Mukherjee S, Crook P, Forlano R, Kont MD, et al. Clinical characteristics and predictors of outcomes of hospitalised patients with COVID-19 in a London NHS Trust: a retrospective cohort study. Clin. Infect. Dis. [Internet]. 2021[acceso 29/04/2020]; 73(11): e4047- 57. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32766823/
- Plasencia-Urizarri TM, Aguilera-Rodríguez R, Almaguer-Mederos LE. Comorbilidades y gravedad clínica de la COVID-19: revisión sistemática y meta-análisis. Rev. habanera cienc. méd. [Internet]. 2020 [acceso 7/07/2020]; 19 (Supl.): e3389. Disponible en: http://www.revhabanera.sld.cu/index.php/ rhab/article/view/3389
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. [Internet]. 2020 [acceso 7/07/2020]; 382(18):1708-20. Disponible en: http://doi.org/10.1056/NEJMoa2002032
- Chih Cheng L, Tzu-Ping S, Wen-Chien K, Hung-Jen T, Po-Ren H. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int.J. Antimicrob. Agents [Internet]. 2020 [acceso 6/04/2020];55(3): [aprox. 23 p.]. Disponible en: http://doi.org/10.1016/j.ijantimicag.2020.105924
- Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging [Internet]. 2020 [acceso 7/07/2020]; 12(7):6049-6057. Disponible en: http://doi.org/10.18632/aging.103000
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 2020[acceso 7/07/2020]; 395(10223):497–506. Disponible en: http://doi.org/ 10.1016/S0140-6736(20)30183-5
- Ministerio de Salud Pública [Internet]. Protocolo de actuación nacional para la COVID-19. 2020. La Habana: MINSAP; 2020. [acceso 5/05/2020]. Disponible en: https://covid19cubadata.github.io/protocolos/protocolo-version-3.pdf
-Ferrer Castro JE, S? nchez Hernández E, Poulout Mendoza A, Del Rio Caballero G, Figueredo Sánchez D. Caracterización clínica y epidemiológica de pacientes confirmados con la COVID-19 en la provincia de Santiago de Cuba. MEDISAN [Internet].2020 [acceso 7/07/2020];24(3), 473-85. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1029-30192020000300473
- Pereda R, Gonzalez D, Rivero HB, Rivero JC, Perez A, Lopez LR, et al. Therapeutic effectiveness of interferon-alpha2b against COVID-19: the Cuban experience. J Interferon Cytokine Res. [Internet].2020 [acceso 7/07/2020];40(9):438-42.Disponible en: https://www.liebertpub.com/doi/10.1089/jir.2020.0124?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed&
- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus diseases 2019 (COVID-19): A review. JAMA [Internet]. 2020 [acceso 17/04/2021];323(18):1824-36. Disponible en: http://doi.org/10.1001/jama.2020.6019
- Gómez Tejeda JJ, DieguezGuach RA, Pérez Abreu MR. Alternativas terapéuticas para el manejo de la COVID-19. Rev haban
cienc méd [Internet]. 2020 [acceso 17/07/2021]; 19(Supl.): e3328. Disponible en:
http://www.revhabanera.sld.cu/index.php/rhab/article/view/3328
- Rodríguez PC, Prada DM, Moreno E, Aira LE, Molinero C, López AM, et al. The anti-CD6 antibody itolizumab provides clinical benefit without ly, phopenia in rheumatoid arthritis patients: results from a 6-month, open-label phase I clinical trial. Clin. Exp. Immunol.[Internet].2018 [acceso 17/07/2021];191(2),229-39. Disponible en: http://doi.org/10.1111/cei.13061
- Aira LE, Lopez-Requena A, Fuentes D, S? nchez L, Pérez T, Urquiza A, et al. Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab. mAbs[Internet]. 2014 [acceso 17/07/2021]; 6(3), 783-92. Disponible en: http://doi.org/10.4161/mabs.28376
- Wang D, Hu B, Hu Ch, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA [Internet]. 2020. [acceso 17/07/2021]; 323(11):1061-69.Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2761044
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China. Lancet Respir Med. [Internet]. 2020 [acceso 17/07/2021];8(5):475-481.Disponible en: http://doi.org/10.1016/S2213-2600(20)30079-5
Published
How to Cite
Issue
Section
License
La Revista Cubana de Higiene y Epidemiologia protege los derechos de autor, y opera con una Licencia Creative Commons 4.0.(Licencia Creative Commons Atribución-No Comercial 4.0 Internacional (CC BY-NC 4.0).Al publicar en ella los autores permiten copiar y redistribuir el material en cualquier medio o formato; remezclar, transformar y crear a partir del material. Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia http://creativecommons.org/licenses/by-nc/4.0/ e indicar si se han realizado cambios. No puede utilizar el material para una finalidad comercial. No hay restricciones adicionales.
Los autores autorizan la publicación de sus escritos conservando los derechos de autoría, y cediendo y transfiriendo a la revista todos los derechos protegidos por las leyes de propiedad intelectual que rigen en Cuba, que implican la edición para difundir la obra.
Los autores podrán establecer acuerdos adicionales para la distribución no exclusiva de la versión de la obra publicada en la revista (por ejemplo, situarla en un repositorio institucional o publicarla en un libro), con el reconocimiento de haber sido publicada primero en esta revista.
